Skip to main content
Erschienen in: Breast Cancer Research 1/2011

Open Access 01.02.2011 | Research article

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals

verfasst von: Kirsi M Kuusisto, Aleksandra Bebel, Mauno Vihinen, Johanna Schleutker, Satu-Leena Sallinen

Erschienen in: Breast Cancer Research | Ausgabe 1/2011

Abstract

Introduction

Two major high-penetrance breast cancer genes, BRCA1 and BRCA2, are responsible for approximately 20% of hereditary breast cancer (HBC) cases in Finland. Additionally, rare mutations in several other genes that interact with BRCA1 and BRCA2 increase the risk of HBC. Still, a majority of HBC cases remain unexplained which is challenging for genetic counseling. We aimed to analyze additional mutations in HBC-associated genes and to define the sensitivity of our current BRCA1/2 mutation analysis protocol used in genetic counseling.

Methods

Eighty-two well-characterized, high-risk hereditary breast and/or ovarian cancer (HBOC) BRCA1/2-founder mutation-negative Finnish individuals, were screened for germline alterations in seven breast cancer susceptibility genes, BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1. BRCA1/2 were analyzed by multiplex ligation-dependent probe amplification (MLPA) and direct sequencing. CHEK2 was analyzed by the high resolution melt (HRM) method and PALB2, RAD50, BRIP1 and CDH1 were analyzed by direct sequencing. Carrier frequencies between 82 (HBOC) BRCA1/2-founder mutation-negative Finnish individuals and 384 healthy Finnish population controls were compared by using Fisher's exact test. In silico prediction for novel missense variants effects was carried out by using Pathogenic-Or-Not -Pipeline (PON-P).

Results

Three previously reported breast cancer-associated variants, BRCA1 c.5095C > T, CHEK2 c.470T > C, and CHEK2 c.1100delC, were observed in eleven (13.4%) individuals. Ten of these individuals (12.2%) had CHEK2 variants, c.470T > C and/or c.1100delC. Fourteen novel sequence alterations and nine individuals with more than one non-synonymous variant were identified. One of the novel variants, BRCA2 c.72A > T (Leu24Phe) was predicted to be likely pathogenic in silico. No large genomic rearrangements were detected in BRCA1/2 by multiplex ligation-dependent probe amplification (MLPA).

Conclusions

In this study, mutations in previously known breast cancer susceptibility genes can explain 13.4% of the analyzed high-risk BRCA1/2-negative HBOC individuals. CHEK2 mutations, c.470T > C and c.1100delC, make a considerable contribution (12.2%) to these high-risk individuals but further segregation analysis is needed to evaluate the clinical significance of these mutations before applying them in clinical use. Additionally, we identified novel variants that warrant additional studies. Our current genetic testing protocol for 28 Finnish BRCA1/2-founder mutations and protein truncation test (PTT) of the largest exons is sensitive enough for clinical use as a primary screening tool.
Hinweise

Electronic supplementary material

The online version of this article (doi:https://​doi.​org/​10.​1186/​bcr2832) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KMK participated patient collection, carried out the sequencing, MLPA and statistical analysis and drafted the manuscript. AB carried out and interpreted the HRM analysis of the CHEK2 gene and helped to draft the methods section of the manuscript. MV performed and interpreted protein prediction analysis in silico and helped to draft the manuscript. JS and S-L S participated in the study design and coordination, and helped to draft the manuscript. S-L S also participated in patient collection and was responsible for genetic counseling of patients. All authors read and approved the final manuscript.
Abkürzungen
BRCA1
breast cancer 1 gene
BRCA2
breast cancer 2 gene
BrCa
breast cancer
BRIP1
BRCA1-interacting protein 1 gene
CDH1
cadherin-1 gene
CHEK2
checkpoint kinase 2 gene
CI
confidence interval
FGFR2
fibroblast growth factor receptor 2 gene
GWAs
genome-wide association studies
HBC
hereditary breast cancer
HBOC
high-risk hereditary breast and/or ovarian cancer
HRM
high resolution melt
miRNA
microRNA
MLPA
multiplex ligation-dependent probe amplification
OR
odds ratio
OvCa
ovarian cancer
PALB2
Partner and localizer of BRCA2
PCR
polymerase chain reaction
PTT
protein truncation test
RAD50
human homolog of S. cerevisiae RAD50 gene
SNP
single nucleotide polymorphism.

Introduction

Breast cancer (BrCa) is the most common cancer among women in Finland, with about 4,000 cases diagnosed yearly (Finnish Cancer Registry). It has been estimated that a monogenic trait accounts for 5 to 10% of all BrCa cases [1]. The two major high-penetrance BrCa genes, BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2), are responsible for 30% of hereditary breast cancer (HBC) cases worldwide, but only for about 20% in Finland [24]. BRCA2 mutations have been found to be more common in the Finnish population than BRCA1 [5]. In addition to BRCA1 and BRCA2 mutations, there are certain hereditary cancer syndromes, such as Li-Fraumeni, Cowden, Peutz-Jeghers and diffuse gastric cancer syndromes, associated with a high risk of BrCa [69]. However, these syndromes very seldom explain HBC.
BRCA1 and BRCA2 have many DNA damage response functions in the cell [10]. Therefore, it has been hypothesized that genes coding for proteins that interact with BRCA1 or BRCA2 or act in the same DNA repair pathway would be likely candidate genes for HBC susceptibility. As expected, CHEK2 (checkpoint kinase 2), PALB2 (partner and localizer of BRCA2), BRIP1 (BRCA1-interacting protein 1), and RAD50 (human homolog of Saccharomyces cerevisiae RAD50) have been shown to have rare, moderate-risk BrCa-associated variants, which have also been studied in the Finnish population [1114]. In addition, BrCa-associated variants have been reported in the CDH1 (cadherin-1) [15].
Although mutations in many genes have been found to predispose an individual to BrCa, approximately 75 to 80% of HBC cases remain unexplained [16]. It is likely that additional BrCa susceptibility gene mutations remain unidentified, especially in the category of moderate- to low-penetrance gene variants that individually confer only minimal risk but that, through multiplicative and/or cumulative effects, can cause relatively high risk for the carriers [17]. Genome-wide association studies (GWAs) have revealed multiple low penetrance, single nucleotide polymorphisms (SNPs) in many genes and chromosomal loci with increased risk of BrCa. For example, SNPs in the fibroblast growth factor receptor 2 (FGFR2) gene have shown significant association with increased risk among BrCa cases with strong family history [18].
To address the problem of heterogeneous HBC in genetic counseling, we wanted to investigate possible additional mutations in HBC-associated genes. The aim of this study was to screen seven known BrCa susceptibility genes for additional mutations in 82 well-characterized, Finnish, high-risk hereditary breast and/or ovarian cancer (HBOC) individuals tested to be BRCA1/2-founder mutation negative. In addition, the sensitivity of our current BRCA1/2 mutation analysis protocol was defined for genetic counseling purposes.

Materials and methods

Patients and controls

Index individuals of 82 high-risk Finnish HBOC families were screened for germline alterations in BrCa-associated genes. All individuals had been detected to be founder mutation-negative by minisequencing of the previously known 28 Finnish BRCA1/2 mutations and by protein truncation test (PTT) of exon 11 for BRCA1 and exons 10 and 11 for BRCA2. Study material had been collected from the individuals, who visited the Tampere University Hospital Genetics Outpatient Clinic between January 1997 and May 2008. The hospital district, in the area of Pirkanmaa, consists of over 20% (1.23 million) of the Finnish population. Individuals were chosen to be included in this study according to the following criteria of high-risk HBC: (a) the individual or her first-degree relative (only female family members were included when defining first-degree relatives) had BrCa or ovarian cancer (OvCa) at younger than 30 years of age; or (b) two first-degree relatives in the family had BrCa and/or OvCa and at least one of the cancers had been diagnosed at younger than 40 years of age; or (c) three first-degree relatives in the family had BrCa and/or OvCa and at least one of the cancers had been diagnosed at younger than 50 years of age; or (d) four or more first-degree relatives had BrCa and/or OvCa at any age; or (e) the same individual had BrCa and OvCa. Patient with bilateral BrCa was considered to have two separate cancers. According to these criteria, our study material also included 11 non-affected females in addition to 71 BrCa and/or OvCa patients. We were also able to get blood samples from two affected relatives in 2 out of 11 separate families with healthy index. These relatives with BrCa were screened for the same variant as that identified in the index. The clinical data of the studied individuals are presented in Table 1. As controls, 384 blood samples from anonymous healthy females, collected from the Finnish Red Cross, were used. All individuals have been informed of the analyses, and they have given written consent to use their already existing DNA samples. Permission for the research project has been received from the Ethical Committee of Tampere University Hospital and the National Authority for Medicolegal Affairs.
Table 1
Characteristics of the studied individuals
 
BrCa
Bil. BrCa
OvCa
BrCa and OvCa
Non-affected
Number of index individuals (n = 82)
57
8
1
5
11
Age at diagnosis
     
(BrCa/OvCa)
n = 57
n = 16a
n = 1
n = 10b
-
<30
13
0
0
1
-
<40 years
11
2
0
2
-
<50 years
15
7
0
2
-
≥50 years
18
7
1
5
-
Type of BrCa
n = 57
n = 16a
-
n = 5
-
Ductal
41
8
-
5
-
Intraductal
2
2
-
0
-
Lobular
9
3
-
0
-
Papillary
1
0
-
0
-
Medullary
1
0
-
0
-
Unknown
3
3
-
0
-
Ductal carcinomas grade known
n = 38
n = 6
 
n = 5
-
Grade 1
7
3
 
0
-
Grade 2
14
3
 
3
-
Grade 3
17
0
 
2
-
ER status known
n = 51
n = 11
-
n = 4
-
ER +
35
10
-
2
-
ER-
16
1
-
2
-
PR status known
n = 50
n = 11
-
n = 4
-
PR+
30
10
-
2
-
PR-
20
1
-
2
-
HER2, status known
n = 46
n = 11
-
n = 4
-
HER2+
14
1
-
1
-
HER2-
32
10
-
3
-
Type of OvCa
-
-
n = 1
n = 5
-
Serous
-
-
0
0
-
Endometrioid
-
-
0
0
-
Mucinous
-
-
0
2
-
Clear cell
-
-
0
1
-
Other
-
-
0
2
-
Unknown
-
-
1
0
-
Number of affected (BrCa/OvCa)
     
first-degree relatives
n = 57
n = 8
n = 1
n = 5
n = 11
≥2
25
3
1
0
5
≥1
24
4
0
0
6
0
8
1
0
5
0
Number of affected (BrCa/OvCa)
     
second-degree relatives
n = 57
n = 8
n = 1
n = 5
n = 11
≥2
5
0
0
0
4
≥1
11
1
0
0
0
0
41
7
1
5
7
Bil. BrCa, bilateral breast cancer; BrCa, breast cancer; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OvCa, ovarian cancer; PR, progesterone receptor. a8 Bilateral breast cancer cases, together 16 cancers, b5 Breast and ovarian cancer cases, together 10 cancers

Mutation detection

DNA samples of the individuals were kindly received from the Tampere University Hospital Genetics Outpatient Clinic. Mutation screening for BRCA1, BRCA2, PALB2, BRIP1, RAD50, and CDH1 was performed by direct sequencing. Whole-coding regions and exon-intron boundaries were analyzed. Primer sequences for PALB2, BRIP1, and RAD50 have been reported previously [12, 13, 19]. Primers for BRCA1 and BRCA2 (excluding previously analyzed exon 11 for BRCA1 and exons 10 and 11 for BRCA2) and CDH1 were designed by using Primer3 software (Rozen and Skaletsky, Whitehead Institute for Biomedical Research, Cambridge, MA, USA) [20]. CHEK2 was screened by using high-resolution melt (HRM) analysis on a Bio-Rad platform (Bio-Rad Laboratories Headquarters, Hercules, CA, USA). Sequencing was carried out using the Big Dye Terminator v.3.1 Cycle Sequencing Kit and ABIPRISM 3130 × l Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Sequences were analyzed with Sequencher v.4.7 software (Gene Codes Corporation, Ann Arbor, MI, USA). Primer sequences, detailed HRM and PCR reaction conditions are available upon request.
Control frequencies were determined for 18 variants by HRM (CHEK2 variants), direct sequencing (BRCA1 c.4883T > C and RAD50 c.1544A > G) and TaqMan® SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) and with an ABI7900 instrument (Applied Biosystems, Foster City, CA, USA). Assays were already designed and functionally tested for the following SNPs: c.8182G > A (rs28897749), c.9976A > T (rs11571833), c.10234A > G (rs1801426), and c.1676A > G (rs152451). As for the c.72A > T, c.814G > A, c.1000T > G, and c.2993G > A (rs45551636) variants, assays were designed by Custom TaqMan® Assay Design Tool (Applied Biosystems, Foster City, CA, USA) according to manufacturer's instructions.
The multiplex ligation-dependent probe amplification (MLPA) analysis was performed for BRCA1 and BRCA2 (SALSA MLPA kit P002-B1 for BRCA1 (lot 0508) and kit P090-A2 for BRCA2 (lot 0808), MRC-Holland, Amsterdam, the Netherlands) according to manufacturer's instructions and analyzed with ABIPRISM 3130xl Genetic Analyzer and Genemapper® v.4.0 software (Applied Biosystems, Foster City, CA, USA).

Statistical analyses

Carrier frequencies between 82 studied individuals and 384 population controls were compared by using Fisher's exact test [21]. All P-values were two sided. Odds ratios (OR) were generated by two-by-two table.

In silico prediction of novel missense variants effects

The effects of five novel-coding missense variants, BRCA2 c.72A > T (Leu24Phe), CHEK2 c.1363G > A (Val455Ile), PALB2 c.814G > A (Glu272Lys), PALB2 c.1000T > G (Tyr334Asp), and RAD50 c.1544A > G (Asp515Gly), were predicted with a number of tools by using Pathogenic-Or-Not-Pipeline (PON-P) [22]. The predictions included those for amino acid tolerance (programs PolyPhen version 2, Sift, PhD-SNP, SNAP) and protein stability (I-Mutant version 3). PON-P allows simultaneous submission of a number of variations and proteins to selected predictors. PON-P utilizes machine learning to combine results from several individual predictions.

MicroRNA database and BLAST search for novel variants

MicroRNA (miRNA) target site search was performed for the novel variant genomic positions from the microRNA database (miRBase) [23]. Also BLAST search [24] was performed for the novel human variant genomic positions to see if these sites are conserved among different organisms including mouse, rat, cow, and chicken.

Results

Index individuals of 82 high-risk HBOC families were screened for germline alterations in BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 genes. Detailed clinical information of analyzed individuals is shown in Table 1. All of the identified 54 sequence variants with their observed genotype frequencies and rs-numbers are presented in Supplementary Table S1 in Additional file 1. All of the identified non-synonymous and novel sequence alterations are summarized in Table 2. Table 2 variants are presented in Table 3 with index individual and family cancer history. In addition, as our study material also included healthy index individuals from 11 families, we made an effort to get blood samples from two affected relatives in 2 out of 11 separate families. These relatives with BrCa were screened for the same variant as that identified in the healthy index. Analysis was performed for the new cases in family 112 (CHEK2 c.470T > C and PALB2 c.1676A > G variants) and family 231 (BRCA1 c.4883T > C variant; Table 3). In family 112, the case proved to have the same PALB2 c.1676A > G variant as the index individual but in family 231, the affected relative did not carry the BRCA1 c.4883T > C variant (data not shown). To further evaluate the impact of these 11 healthy index cases, we recalculated the frequencies without these 11 individuals for those variants accepted to be meaningful for BrCa risk. Supplementary Table S2 in Additional file 2 shows these re-calculated frequencies for BRCA1 c.5095C > T, CHEK2 c.470T > C, and CHEK2 c.1100delC variants. No statistically significant effect was seen for exclusion of the 11 cases.
Table 2
Identified non-synonymous and novel sequence alterations
   
Carrier frequency
   
Gene/Nucleotide changea
Effect on protein
rs Numberb
Individuals
Controls
P-values
OR; 95%CI
Status
BRCA1
       
4837A > G
Ser1613Gly
rs1799966
0.634 (52/82)g
na
-
-
Reportedc, d
4883T > C
Met1628Thr
rs4986854
0.049 (4/82)
0.016 (6/367)
0.090
3.09; 0.85-11.19
Reportedc, d
5095C > T
Arg1699Trp
rs55770810
0.012 (1/82)
na
-
-
Reportedc, d
BRCA2
       
68-80insTf
-
-
0.012 (1/82)
na
-
-
Novel
72A > T
Leu24Phe
-
0.012 (1/82)
0 (0/380)
0.177
na
Novel
793 + 34T > G
-
-
0.012 (1/82)
na
-
-
Novel
8182G > A
Val2728Ile
rs28897749
0.012 (1/82)
0.003 (1/378)
0.325
4.65; 0.29-75.19
Reportedc, d
9976A > T
Lys3326Stop
rs11571833
0.012 (1/82)
0.029 (11/378)
0.702
0.41; 0.05-3.24
Reportedc, d
10234A > G
Ile3412Val
rs1801426
0.012 (1/82)
0.021 (8/379)
1.000
0.57; 0.07-4.64
Reportedc, d
CHEK2
       
444 + 85T > A
-
-
0.012 (1/82)
0.005 (2/364)
0.457
2.23; 0.20-24.94
Novel
470T > C
Ile157Thr
-
0.098 (8/81)
0.055 (21/381)
0.203
1.88; 0.80-4.41
Reportede
792 + 39C > T
-
-
0.012 (1/82)
0.021 (8/375)
1.000
0.57; 0.07-4.60
Novel
1100delCf
Fs, stop at codon 381
-
0.037 (3/82)
0.016 (6/380)
0.203
2.37; 0.58-9.67
Reportede
1290T > C
His430His
-
0.951 (77/81)g
0.974 (372/382)
0.281
0.52; 0.16-1.69
Novel
1314T > C
Asp438Asp
-
0.951 (77/81)g
0.974 (372/382)
0.281
0.52; 0.16-1.69
Novel
1363G > A
Val455Ile
-
0.975 (79/81)g
0.976 (373/382)
1.000
0.95; 0.20-4.50
Novel
PALB2
       
814G > A
Glu272Lys
-
0.012 (1/82)
0 (0/372)
0.181
na
Novel
1000T > G
Tyr334Asp
-
0.012 (1/82)
0.011 (4/380)
1.000
1.16; 0.13-10.52
Novel
1010T > C
Leu337Ser
rs45494092
0.073 (6/82)
na
-
-
Reportedc
1676A > G
Gln559Arg
rs152451
0.122 (10/82)
0.173 (64/371)
0.323
0.67; 0.33-1.36
Reportedc
2205A > G
Pro735Pro
-
0.012 (1/82)
na
-
-
Novel
2794G > A
Val932Met
rs45624036
0.037 (3/82)
na
-
-
Reportedc
2993G > A
Gly998Glu
rs45551636
0.012 (1/82)
0.038 (14/372)
0.491
0.32; 0.04-2.44
Reportedc
BRIP1
       
584T > C
Leu195Pro
rs4988347
0.024 (2/82)
na
-
-
Reportedc
2755C > T
Pro919Ser
rs4986764
0.390 (32/82)g
na
-
-
Reportedc
RAD50
       
1544A > G
Asp515Gly
-
0.012 (1/82)
0.010 (4/384)
1.000
1.17; 0.13-10.63
Novel
2398-32A > G
-
-
0.012 (1/82)
na
-
-
Novel
3475 + 33C > G
-
-
0.012 (1/82)
na
-
-
Novel
CI, confidence interval; Fs, frameshift; na, not analyzed; OR, odds ratio. aThe reference nucleotide sequencies were obtained from the UCSC Genome Browser [44] and the accession numbers were following: BRCA1: [UCSC Genome Browser:NM_007295.2], BRCA2: [UCSC Genome Browser:NM_000059.3], CHEK2: [UCSC Genome Browser:NM_007194.3], PALB2: [UCSC Genome Browser:NM_024675.3], BRIP1: [UCSC Genome Browser:NM_032043.1], RAD50: [UCSC Genome Browser:NM_005732.3], and CDH1: [UCSC Genome Browser:NM_004360.3]. The accession numbers for the protein sequencies obtained from the Swiss-Prot Protein knowledgebase [45] were following: BRCA1: [Swiss-Prot:P38398], BRCA2: [Swiss-Prot:P51587], CHEK2: [Swiss-Prot:O96017], PALB2: [Swiss-Prot:Q86YC2], BRIP1: [Swiss-Prot:Q9BX63], RAD50: [Swiss-Prot:Q92878], and CDH1: [Swiss-Prot:P12830]. bThe RefSNP number, obtained from the NCBI Single Nucleotide Polymorphism database (dbSNP) [46]. cThe NCBI dbSNP [46]. dThe Breast Cancer Information Core database [47]. eReported in the Finnish population by Vahteristo et al. [11]. fHeterozygous deletion or insertion.gDue to the high frequency of the variant observed in analyzed individuals, variant is not presented in Table 3.
Table 3
Identified variants in the studied individuals
Family id
Gene and variant
Type of cancer
BrCa/OvCa Histology,Grade
Receptor status
Other cancer cases in the family (Age at diagnosis if available)
202
BRCA1, 4883T > C
Br (26)
Ductal, 3
ER-, PR-, HER2-
Skin (54)
206
BRCA1, 4883T > C
Br (53)
Ductal, 1
ER-, PR-, HER2-
Bil. Ov (64), Br (49)
231
BRCA1, 4883T > C
-
  
Br x2 (33, 46), Cer (60), Skin (73)
232
BRCA1, 4883T > C
Br (34)
Ductal, na
ER +, PR +, HER2 na
Br (39)
249 (Figure 1)
BRCA1, 5095C > T
Br (42)
Medullary, na
na
Br x5 (35, 44, 57, 67, 71, ),
     
Co (78), Kid (67), Mel (63), Ov (45),
     
Skin, To (51), Ute (39)
115
BRCA2, 68-80insT
Br (59)
Lobular, 2
ER+, PR+, HER2-
Br x3 (<50), Br x2 (60, 60)
240
BRCA2, 72A > T
Br (53)
Ductal, 3
ER+, PR-, HER2+
Br x2 (42, 62)
207
BRCA2, 793 + 34T > G
Br (38)
na
na
Bil. Br (64)
5 (Figure 8)
BRCA2, 8182G > A
-
  
Bil. Br x2 (43, 48 and 54, 76),
 
BRCA2, 10234A > G
   
Br (43), Brain (75), Lip (45), Lung (81), Skin (75), Sto (56)
4
BRCA2, 9976A > T
-
  
Bil. Br x2 (53, 69 and <70),
 
CHEK2, 470T > C
   
Br (<70)
212
CHEK2, 444 + 85T > A
Bil. Br (43)
Ductal, 2 and na
ER+, PR+, HER2- and
Br (52)
 
PALB2, 2794G > A
  
na
 
110 (Figure 3)
CHEK2, 792 + 39C > T
Br (26)
Ductal, 2
ER+, PR+, HER2+
Br (48), Ca (84), Pr (64)
 
CHEK2, 470T > C
    
 
CHEK2, 1100delC
    
 
RAD50, 2398-32A > G
    
112
CHEK2, 470T > C
-
  
Br x3 (35, 43, 83), Skin (76),
 
PALB2, 1676A > G
   
Lung (71)
120
CHEK2, 470T > C
-
  
Br (64), Ov (72)
122
CHEK2, 470T > C
Br (25)
Ductal, 2
ER-, PR-, HER2+
Brain (66, Ca (83),Cer (31),
     
Pr (93), Re (73), Skin (87)
126
CHEK2, 470T > C
Br (48)
Ductal, na
ER, PR, HER2 na
Bil. Br, Br x2 (51, <53)
129 (Figure 2)
CHEK2, 470T > C
Skin (70),
Lobular, 2 and
ER-, PR-, HER2- and
Bil. Br (59), Co (58), Skin (48)
 
PALB2, 1676A > G
Bil. Br (78),
Ductal, 1
ER+, PR+, HER2-
 
  
Sto (82)
   
262 (Figure 6)
CHEK2, 470T > C
Bil. Br
Intraductal, na and
ER+, PR+, HER2+ and
Br (57), Panc (83), Si (79)
 
PALB2, 1000T > G
(45, 58)
Ductal, na
ER+, PR+, HER2-
 
264 (Figure 4)
CHEK2, 1100delC
Bil. Br (44)
Lobular, 2
ER+, PR+, HER2-
Br x2 (44, 52)
265 (Figure 5)
CHEK2, 1100delC
Br (45)
Ductal, 3
ER+, PR+, HER2+
Br (38)
 
PALB2, 1676A > G
    
237
PALB2, 814G > A
Br (28)
Ductal, 2
ER+, PR+, HER2+
-
133
PALB2, 1010T > C
Br (48)
Ductal, 2
ER+, PR+, HER2-
Int, Br x2 (73, 79), Skin (60)
235
PALB2, 1010T > C
Br (52)
na
na
Bil. Br (28), Br (56)
239
PALB2, 1010T > C
Br (37)
Ductal, 2
ER+, PR+, HER2-
Br ( > 90)
250
PALB2, 1010T > C
Br (24)
Ductal, 3
ER+, PR+, HER2+
Cer (30), Ov (83)
260
PALB2, 1010T > C
Br (29)
Ductal, 3
ER-, PR-, HER2-
Br (58), Lung (60)
267
PALB2, 1010T > C
Br (48)
Ductal, 1
ER+, PR+, HER2 na
Br x2 (51, 58)
113
PALB2, 1676A > Ga
Br (51),
Ductal, 3
ER-, PR-, HER2+
Br (35)
  
Skin (55)
   
131 (Figure 7)
PALB2, 1676A > G
Bil. Br (54)
Intraductal, na and
na
Bil. Br (46), Br (48)
 
BRIP1, 584T > C
 
Ductal, 2
  
229
PALB2, 1676A > G
Bil. Br (68)
na
na
Bil. Br (50, 70), Br x2 (45, 50)
236
PALB2, 1676A > G
Br (29)
Intraductal, na
na
Br (52)
246
PALB2, 1676A > G
Thy (30),
Ductal, 3
ER-, PR-, HER2+
Br x2 (49, 54), Re (61)
  
Cer (33),
   
  
Br (39)
   
268
PALB2, 1676A > G
Br (62)
Papillary, na
ER+, PR+, HER2-
Br x2 (36, 38)
 
PALB2, 2205A > G
    
271
PALB2, 1676A > G
Thy (62),
Lobular, 2
ER+, PR+, HER2-
Br x2 (43, 44)
  
Br (65)
   
102
PALB2, 2794G > A
Br (29)
Lobular, na
ER-, PR-, HER2+
Br (72)
 
BRIP1, 584T > C
    
244
PALB2, 2794G > A
Br (45)
Ductal, 2
ER+, PR+, HER2-
Bil. Br (<45), Br x2 (<35, 46),
     
Brain (67)
270
PALB2, 2993G > A
Br (66)
Ductal, 3
ER+, PR+, HER2-
Br x2 (48, <66)
257
RAD50, 1544A > G
Br (39)
Lobular, 2
ER+, PR+, HER2-
Br (69)
225
RAD50, 3475+33C > G
Br (43)
Ductal, 1
ER+, PR+, HER2-
Br x2 (52, 77), Kid (64)
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; na, not available; Bil, Bilateral; Br, breast; Ca, cancer with unknown primary site; Cer, cervix; Co, colon; Int, intestines; Kid, kidney; Mel, melanoma; Ov, ovary; Panc, pancreas; Pr, prostate; Re, rectum; Si, Sigma; Sto, stomach; Thy, thyroid; To, tongue; Ute, uterus. aHomozygous variant. Cancers diagnosed in the paternal side of the family are presented in italics. Cancers diagnosed in siblings or their children of the index patients are underlined. Cancers diagnosed in the children of the index patients are presented in bold.

BRCA1 and BRCA2 mutation analysis

Analysis of BRCA1 and BRCA2 revealed altogether 16 different sequence variants, seven in BRCA1 and nine in BRCA2 [see Supplementary Table S1 in Additional file 1]. All but two of the identified variants in BRCA1, c.4883T > C and c.5095C > T, have been reported to be neutral in the databases. Heterozygous c.4883T > C variant was observed in 4 of 82 (4.9%) women of which three had BrCa and one had a family history of breast, cervix and skin cancers (Tables 2 and 3). In population controls, the frequency of the c.4883T > C variant was 6 of 367 (1.6%). The c.5095C > T variant has been classified as a deleterious mutation in the Breast Cancer Information Core (BIC) database. The heterozygous c.5095C > T mutation was observed in 1 of 82 (1.2%) women. The mutation carrying woman had BrCa diagnosed at the age of 42 years and a strong family history of cancer (Tables 2 and 3, Figure 1, Family 249). Additional mutation analysis also revealed two other affected women carrying the c.5095C > T mutation in the same family. In BRCA2, three of the nine identified variants were novel, c.68-80insT, c.72A > T, and c.793 + 34T > G (Tables 2 and 3.). The heterozygous missense variant c.72A > T (Leu24Phe), was observed in 1 of 82 (1.2%) women but not in population controls. The c.72A > T variant carrying woman had BrCa diagnosed at the age of 53 years. She had also two affected first-degree relatives (mother and sister). Protein predictions by PON-P suggested that substitution of leucine by phenylalanine in position 24 changes significantly the properties of the side chain and the substitution would not be tolerated. All the other identified variants in BRCA2 have been reported previously and they are either neutral or the clinical significance of the variants is yet uncertain especially with the three missense variants, c.8182G > A, c.9976A > T and c.10234A > G (Tables 2 and 3). No deletions or duplication were identified either in BRCA1 or BRCA2 by multiplex ligation-dependent probe amplification (MLPA).

CHEK2 mutation analysis

In CHEK2, two previously reported BrCa-associated variants in the Finnish population, c.470T > C and c.1100delC, were identified in 10 of 82 (12.1%) individuals (Tables 2 and 3). The heterozygous c.470T > C variant was observed in eight women of which three were healthy. Two of the c.470T > C variant carriers had bilateral BrCa and they carried also PALB2 missense variants (an example of the family pedigree of the index individual carrying the both variants is presented in Figure 2, Family 129). The heterozygous c.1100delC variant was detected in three women (Tables 2 and 3). One woman carrying c.1100delC with an early-onset disease of 26 years of age also carried the c.470T > C and the novel c.792 + 39C > T CHEK2 variants as well as the RAD50, c.2398-32A > G variant (Figure 3, Family 110). A second patient with the c.1100delC variant had bilateral BrCa at the age of 44 years and two other affected individuals in her family (mother and father's sister; Figure 4, Family 264). A third patient with the c.1100delC variant had BrCa diagnosed at the age of 45 years and one affected individual (mother) in her family. This woman carried also the PALB2 c.1676A > G variant (Figure 5, Family 265). In addition to c.470T > C and c.1100delC, five novel variants (Table 2) and one common polymorphism [see Supplementary Table S1 in Additional file 1] were identified in CHEK2. The novel non-synonymous variant, c.1363G > A (Val455Ile), is based on the computational predictions, and is likely benign.

PALB2 mutation analysis

In PALB2, altogether nine different variants, including three novel ones, were identified [see Supplementary Table S1 in Additional file 1]. Only one of the identified variants reported previously, c.2586 + 58C > T, has been associated with a 36% increase of BrCa risk (odds ratio (OR): 1.36; 95% confidence intervals (CIs), 1.13-1.64; P = 0.001) in a Chinese population [25]. We identified the c.2586 + 58C > T variant in 36 of 82 (43.9%) women. A novel heterozygous c.814G > A variant was identified in 1 of 82 (1.2%) women but not in population controls (Tables 2 and 3). The c.814G > A variant carrying woman had BrCa diagnosed at the age of 28 years, but no other affected individuals were seen in her family. The c.814G > A variant results in amino acid substitution of glutamic acid to lysine at position 272, which causes a significant change to side chain properties including size and change of the charge to opposite. However, protein predictions by PON-P suggest that variation is neutral. The second novel heterozygous variant, c.1000T > G (Tyr334Asp), was observed in 1 of 82 (1.2%) women and in 4 of 380 (1.1%) population controls. The c.1000T > G variant carrying woman had bilateral BrCa diagnosed at the ages of 45 and 58 years and a family history of three other cancers (Tables 2 and 3, Figure 6, Family 262). She carried also the CHEK2 c.470T > C variant. However, the protein predictions for the c.1000T > G (Tyr334Asp) variant suggest it to be neutral. A third novel heterozygous variant, c.2205A > G (Pro735Pro), is silent and likely to be neutral. It was observed in 1 of 82 (1.2%) women (Tables 2 and 3). Previously reported PALB2 missense variants, c.1010T > C, c.1676A > G, c.2794G > A, and c.2993G > A were identified here with frequencies from 1.2% to 12.2% in analyzed individuals (Tables 2 and 3) but the variants have not been associated with BrCa risk (an example of the family pedigree of the index individual carrying the c.1676A > G variant in addition to the BRIP1 c.584T > C variant is presented in Figure 7, Family 131).

BRIP1, RAD50, and CDH1 mutation analysis

In BRIP1, two silent [see Supplementary Table S1 in Additional file 1] and two missense variants (Tables 2 and 3) were identified. All of the identified variants have been reported previously and they are likely to be neutral. In RAD50, altogether seven sequence alterations were observed [see Supplementary Table S1 in Additional file 1] and three of these were novel (Table 2). The novel missense variant, c.1544A > G (Asp515Gly), was observed in 1 of 82 (1.2%) women and in 4 of 384 (1.1%) population controls. The c.1544A > G variant carrying woman had BrCa diagnosed at the age of 39 years and one affected first-degree relative (Table 3). According to protein predictions, c.1544A > G variant is likely to be neutral. Two other novel variants, c.2398-32A > G and c.3475 + 33C > G, were both observed with the frequency of 1 of 82 (1.2%) in analyzed individuals (Tables 2 and 3). In CDH1, 10 different sequence alterations were identified [see Supplementary Table S1 in Additional file 1]. All of the variants have been reported previously and they are likely neutral.

MicroRNA database and BLAST search for novel variants

No known miRNA target sites were found in the identified novel variant genomic positions. In BLAST search, BRCA2 c.72A > T variant position was found to have sequence similarities between rat and cow. RAD50 c.1544A > G variant position shared similarities with mouse, rat, cow and chicken. Three novel variant positions in CHEK2 exon 11 and the RAD50 c.3475 + 33C > G variant shared sequence similarity between mouse, rat and cow. Variants that occur in the genomic regions that are conserved across species may indicate a pathogenic role.

Discussion

In the present study, we screened BrCa susceptibility genes in 82 Finnish high-risk HBOC individuals with no known Finnish BRCA1/2-founder mutations. As genetic counseling and surveillance is greatly needed for these individuals and their families, we decided to study BRCA1/2 in more detail and also to analyze five additional genes that had previously been associated with BrCa risk.
The majority of known BRCA1/2 alterations are small insertions and deletions or point mutations (BIC database). Also, large genomic rearrangements have been reported in both genes with varying frequencies in different populations [26]. In Finland, so far only Pylkäs et al. have reported a large deletion in BRCA1 identified in a Finnish OvCa family [27]. In our study, no deletions or duplications were found in either BRCA1 or BRCA2 by MLPA, which suggests the existence of more restricted alterations. A total of 16 different sequence variants were identified from these two genes [see Supplementary Table S1 in Additional file 1] and only one of the identified variants, c.5095C > T in BRCA1, has been classified as a clinically significant mutation in the BIC database. In line with this classification, our BrCa patient carrying this variant had a strong family history of cancer (Tables 2 and 3, Figure 1, Family 249) and two other variant carriers with BrCa were also observed in the same family. The c.5095C > T mutation thus can explain a fraction of the BrCa cases also in the Finnish population. The clinical significance of the BRCA1 c.4883T > C variant in BrCa predisposition is uncertain [28, 29]. Our data support the idea that it is a low-penetrant risk allele, because the variant was observed to be three times more common in analyzed high-risk individuals than healthy population controls (Tables 2 and 3). Novel variant findings in BRCA2 (Tables 2 and 3) warrant additional studies, especially the novel missense variant, c.72A > T (Leu24Phe), which was shown not to be tolerated by protein prediction. Prediction indicated that the substitution decreases the stability of the produced protein and this might be the mechanism behind the disease for this variant. The amino acid position 24 is located near the N-terminal part of BRCA2. Amino acids 1 to 40 interact with PALB2, and sequence variants in this region have been shown to have effects on the PALB2 and BRCA2 interaction and thus are suspected to have a role in cancer predisposition [30]. The role of the three BRCA2 missense variants, c.8182G > A, c.9976A > T, and c.10234A > G, in HBOC risk, is uncertain [3133]. All three heterozygous variants were observed in two healthy women with a history of BrCa, one carrying the c.9976A > T variant and the other both the c.8182G > A and c.10234A > G variants (Tables 2 and 3, Figure 8, Family 005). At this stage, because we only have samples from the index individuals, no segregation analyses of the variants have been performed, but these families clearly warrant additional studies. In recent risk models, it has been suggested that multiple low-risk variants within the same individual may actually cause a significantly elevated risk for the carrier [17]. The overall low frequency of new variants identified in BRCA1/2 genes suggests that the present protocol for testing 28 Finnish BRCA1/2-founder mutations and PTT of the largest exons is adequate for clinical use to detect the majority of harmful mutations in these two genes in the Finnish population.
Two of the CHEK2 variants, c.470T > C and c.1100delC, have been widely studied in BrCa predisposition in Finland and elsewhere. Previous studies have shown that the c.1100delC allele confers about a two-fold elevated BrCa risk in women, whereas c.470T > C is a lower risk variant [34, 35]. Both variants also associate with other cancers in the Finnish population [3638]. In our study, two of the CHEK2 variants, c.470T > C and c.1100delC, were identified in 10 out of 82 analyzed individuals (12.2%) suggesting that the contribution of the two CHEK2 variants to BrCa risk is remarkable in the high-risk Finnish BRCA1/2-founder mutation-negative individuals. However, clinical screening of the CHEK2 variants has not yet been justified due to unclear clinical consequences related to incomplete segregation of the variants with BrCa in the high-risk BrCa families [39, 40]. Based on the findings of this study, we agree that interpretation of the CHEK2 mutation analysis results is very difficult, because many other gene variants were also identified in individuals with either c.470T > C or c.1100delC variants and some of the variant carriers had not (yet) been diagnosed with BrCa. Thus profound segregation analysis of the c.470T > C and c.1100delC variants for BRCA1/2-founder mutation-negative families would be needed to further study clinical significance of these variants. Also the novel variants identified in CHEK2 should be further analyzed.
PALB2 has been associated with BrCa predisposition in Finland by Erkko et al. [12] and the c.1592delT variant was classified as a Finnish founder mutation. In this study the founder deletion was not found, which is probably explained by the limited number of analyzed high-risk HBOC individuals. We identified two novel PALB2 missense variants, c.814G > A (Glu272Lys) and c.1000T > G (Tyr334Asp), in affected individuals (Tables 2 and 3). Protein predictions suggested a non-pathogenic role of these substitutions but further studies are needed to confirm these findings. None of the four previously reported PALB2 missense variants, c.1010T > C, c.1676A > G, c.2794G > A, and c.2993G > A, have been associated with BrCa risk [12, 41]. Interestingly, these variants were identified also together with other variants in analyzed individuals (Tables 2 and 3). One of the identified intronic variants, c.2586 + 58C > T, has been associated with an increase of BrCa risk in a Chinese population [25] but there is no evidence of that in the Finnish population.
BRIP1 and RAD50 genes have been shown to have rare BrCa associated variants in familial BrCa patients [14, 42]. Here, BRIP1 mutation analysis revealed only previously reported likely neutral variants. Whereas analysis of RAD50 identified three novel sequence alterations, including one missense variant, c.1544A > G (Asp515Gly) (Tables 2 and 3). To further study the role of these novel variants, additional analyses are needed. Germline mutations in CDH1 have been previously found to associate with hereditary diffuse gastric cancer syndrome, but mutations have been also identified in familial invasive lobular BrCa patients without hereditary diffuse gastric cancer [15, 43]. Here, only neutral variants were identified, and all of them have been reported earlier [see Supplementary Table S1 in Additional file 1]. No clear results were found that any of the identified genetic variants in BRIP1, RAD50, or CDH1 would increase the BrCa/OvCa risk in the analyzed high-risk Finnish HBOC individuals.

Conclusions

In this study, 13.4% of the analyzed, high-risk BRCA1/2-founder mutation-negative HBOC cases can be explained by previously reported mutations in BrCa susceptibility genes. CHEK2 mutations, c.470T > C and c.1100delC, make a considerable contribution (12.2%) to these high-risk individuals but further segregation analysis are needed to evaluate the clinical significance of these mutations before applying them in clinical use. Novel variant findings warrant additional studies with special interest in the novel missense variant, BRCA2 c.72A > T (Leu24Phe), which was predicted to bear untolerated mutations and to destabilize the protein. The complex nature of HBOC addresses the need for genome-wide approaches to further study these individuals and to create new tools for genetic counseling. This study also confirmed that our current genetic testing protocol for the 28 Finnish BRCA1/2-founder mutations and PTT of the largest exons is sensitive enough for clinical use in the majority of Finnish HBC/HBOC individuals.

Acknowledgements

We thank all the patients for their participation into this study. We also thank personnel of the Tampere University Hospital Genetics Outpatient Clinic and JS's research group for all the help. Special thanks are given to Ms. Linda Enroth for skillful technical assistance. Also Ms. Ekaterina Slitikova and Ms. Aune Aho are greatly acknowledged for their contribution. Funding: This work was supported by the Competitive Research Funding of the Tampere University Hospital (9K119, ML16), Biocentre Finland and Sigrid Juselius Foundation. The Finnish Cultural Foundation and the Finnish Breast Cancer Group have financially supported author KMK.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KMK participated patient collection, carried out the sequencing, MLPA and statistical analysis and drafted the manuscript. AB carried out and interpreted the HRM analysis of the CHEK2 gene and helped to draft the methods section of the manuscript. MV performed and interpreted protein prediction analysis in silico and helped to draft the manuscript. JS and S-L S participated in the study design and coordination, and helped to draft the manuscript. S-L S also participated in patient collection and was responsible for genetic counseling of patients. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer. 1996, 77 (11): 2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z.CrossRef Claus EB, Schildkraut JM, Thompson WD, Risch NJ: The genetic attributable risk of breast and ovarian cancer. Cancer. 1996, 77 (11): 2318-2324. 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z.CrossRef
2.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266 (5182): 66-71. 10.1126/science.7545954.CrossRef Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266 (5182): 66-71. 10.1126/science.7545954.CrossRef
3.
Zurück zum Zitat Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996, 12: 333-337. 10.1038/ng0396-333.CrossRef Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996, 12: 333-337. 10.1038/ng0396-333.CrossRef
4.
Zurück zum Zitat Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRef Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRef
5.
Zurück zum Zitat Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000, 92: 1529-1531. 10.1093/jnci/92.18.1529.CrossRef Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2000, 92: 1529-1531. 10.1093/jnci/92.18.1529.CrossRef
6.
Zurück zum Zitat Li FP, Fraumeni JF: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969, 43: 1365-1373.PubMed Li FP, Fraumeni JF: Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969, 43: 1365-1373.PubMed
7.
Zurück zum Zitat Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, Eriksson AW: The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986, 29: 222-233. 10.1111/j.1399-0004.1986.tb00816.x.CrossRef Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, Eriksson AW: The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986, 29: 222-233. 10.1111/j.1399-0004.1986.tb00816.x.CrossRef
8.
Zurück zum Zitat Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000, 119: 1447-1453. 10.1053/gast.2000.20228.CrossRef Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000, 119: 1447-1453. 10.1053/gast.2000.20228.CrossRef
9.
Zurück zum Zitat Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H: Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999, 155: 337-342. 10.1016/S0002-9440(10)65129-2.CrossRef Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, Hofler H: Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999, 155: 337-342. 10.1016/S0002-9440(10)65129-2.CrossRef
10.
Zurück zum Zitat Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000, 16: 69-74. 10.1016/S0168-9525(99)01930-7.CrossRef Welcsh PL, Owens KN, King MC: Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000, 16: 69-74. 10.1016/S0168-9525(99)01930-7.CrossRef
11.
Zurück zum Zitat Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRef Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRef
12.
Zurück zum Zitat Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen S, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma V, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R: A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007, 446: 316-319. 10.1038/nature05609.CrossRef Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen S, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma V, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R: A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007, 446: 316-319. 10.1038/nature05609.CrossRef
13.
Zurück zum Zitat Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H: BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer. 2006, 6: 19-10.1186/1471-2407-6-19.CrossRef Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H: BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer. 2006, 6: 19-10.1186/1471-2407-6-19.CrossRef
14.
Zurück zum Zitat Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T, Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R: RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006, 27: 1593-1599. 10.1093/carcin/bgi360.CrossRef Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundan T, Mannermaa A, Borresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R: RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis. 2006, 27: 1593-1599. 10.1093/carcin/bgi360.CrossRef
15.
Zurück zum Zitat Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature. 1998, 392: 402-405. 10.1038/32918.CrossRef Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE: E-cadherin germline mutations in familial gastric cancer. Nature. 1998, 392: 402-405. 10.1038/32918.CrossRef
16.
Zurück zum Zitat Easton DF: How many more breast cancer predisposition genes are there?. Breast Cancer Res. 1999, 1: 14-17. 10.1186/bcr6.CrossRef Easton DF: How many more breast cancer predisposition genes are there?. Breast Cancer Res. 1999, 1: 14-17. 10.1186/bcr6.CrossRef
17.
Zurück zum Zitat Antoniou AC, Easton DF: Models of genetic susceptibility to breast cancer. Oncogene. 2006, 25: 5898-5905. 10.1038/sj.onc.1209879.CrossRef Antoniou AC, Easton DF: Models of genetic susceptibility to breast cancer. Oncogene. 2006, 25: 5898-5905. 10.1038/sj.onc.1209879.CrossRef
18.
Zurück zum Zitat Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.CrossRef Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.CrossRef
19.
Zurück zum Zitat Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N: Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer. 2006, 118: 2911-2916. 10.1002/ijc.21738.CrossRef Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkila P, Evans DG, Eccles D, Aittomaki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N: Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer. 2006, 118: 2911-2916. 10.1002/ijc.21738.CrossRef
20.
Zurück zum Zitat Rozen S, Skaletsky H: Primer3 on the www for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.PubMed Rozen S, Skaletsky H: Primer3 on the www for general users and for biologist programmers. Methods Mol Biol. 2000, 132: 365-386.PubMed
22.
Zurück zum Zitat Thusberg J, Vihinen M: Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat. 2009, 30: 703-714. 10.1002/humu.20938.CrossRef Thusberg J, Vihinen M: Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. Hum Mutat. 2009, 30: 703-714. 10.1002/humu.20938.CrossRef
25.
Zurück zum Zitat Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, Wang H: Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res. 2008, 14: 5931-5937. 10.1158/1078-0432.CCR-08-0429.CrossRef Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, Wang H: Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin Cancer Res. 2008, 14: 5931-5937. 10.1158/1078-0432.CCR-08-0429.CrossRef
26.
Zurück zum Zitat Mazoyer S: Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. 2005, 25: 415-422. 10.1002/humu.20169.CrossRef Mazoyer S: Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. 2005, 25: 415-422. 10.1002/humu.20169.CrossRef
27.
Zurück zum Zitat Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R: Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer. 2008, 8: 146-10.1186/1471-2407-8-146.CrossRef Pylkas K, Erkko H, Nikkila J, Solyom S, Winqvist R: Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer. 2008, 8: 146-10.1186/1471-2407-8-146.CrossRef
28.
Zurück zum Zitat Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA: The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet. 2004, 153: 177-180. 10.1016/j.cancergencyto.2004.01.020.CrossRef Ostrow KL, McGuire V, Whittemore AS, DiCioccio RA: The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity. Cancer Genet Cytogenet. 2004, 153: 177-180. 10.1016/j.cancergencyto.2004.01.020.CrossRef
29.
Zurück zum Zitat Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, kConFab , Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN: Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet. 2005, 42: 138-146. 10.1136/jmg.2004.024711.CrossRef Phelan CM, Dapic V, Tice B, Favis R, Kwan E, Barany F, Manoukian S, Radice P, van der Luijt RB, van Nesselrooij BP, Chenevix-Trench G, kConFab , Caldes T, de la Hoya M, Lindquist S, Tavtigian SV, Goldgar D, Borg A, Narod SA, Monteiro AN: Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet. 2005, 42: 138-146. 10.1136/jmg.2004.024711.CrossRef
30.
Zurück zum Zitat Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM: Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006, 22: 719-729. 10.1016/j.molcel.2006.05.022.CrossRef Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM: Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006, 22: 719-729. 10.1016/j.molcel.2006.05.022.CrossRef
31.
Zurück zum Zitat Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL: Characterization of common BRCA1 and BRCA2 variants. Genet Test. 2002, 6: 119-121. 10.1089/10906570260199375.CrossRef Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL: Characterization of common BRCA1 and BRCA2 variants. Genet Test. 2002, 6: 119-121. 10.1089/10906570260199375.CrossRef
32.
Zurück zum Zitat Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P: Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999, 8: 413-423. 10.1093/hmg/8.3.413.CrossRef Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P: Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999, 8: 413-423. 10.1093/hmg/8.3.413.CrossRef
33.
Zurück zum Zitat Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM: A polymorphic stop codon in BRCA2. Nat Genet. 1996, 14: 253-254. 10.1038/ng1196-253.CrossRef Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM: A polymorphic stop codon in BRCA2. Nat Genet. 1996, 14: 253-254. 10.1038/ng1196-253.CrossRef
34.
Zurück zum Zitat CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004, 74: 1175-1182. 10.1086/421251.CrossRef CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004, 74: 1175-1182. 10.1086/421251.CrossRef
35.
Zurück zum Zitat Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H: CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 2004, 111: 543-547. 10.1002/ijc.20299.CrossRef Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H: CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 2004, 111: 543-547. 10.1002/ijc.20299.CrossRef
36.
Zurück zum Zitat Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer. 2003, 89: 1966-1970. 10.1038/sj.bjc.6601425.CrossRef Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J: CHEK2 variants associate with hereditary prostate cancer. Br J Cancer. 2003, 89: 1966-1970. 10.1038/sj.bjc.6601425.CrossRef
37.
Zurück zum Zitat Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H: CHEK2 1100delC and colorectal cancer. J Med Genet. 2003, 40: e110-10.1136/jmg.40.10.e110.CrossRef Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H: CHEK2 1100delC and colorectal cancer. J Med Genet. 2003, 40: e110-10.1136/jmg.40.10.e110.CrossRef
38.
Zurück zum Zitat Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H: CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet. 2006, 43: e34-10.1136/jmg.2005.038331.CrossRef Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H: CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet. 2006, 43: e34-10.1136/jmg.2005.038331.CrossRef
39.
Zurück zum Zitat Nevanlinna H, Bartek J: The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006, 25: 5912-5919. 10.1038/sj.onc.1209877.CrossRef Nevanlinna H, Bartek J: The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006, 25: 5912-5919. 10.1038/sj.onc.1209877.CrossRef
40.
Zurück zum Zitat Ripperger T, Gadzicki D, Meindl A, Schlegelberger B: Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet. 2009, 17: 722-731. 10.1038/ejhg.2008.212.CrossRef Ripperger T, Gadzicki D, Meindl A, Schlegelberger B: Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet. 2009, 17: 722-731. 10.1038/ejhg.2008.212.CrossRef
41.
Zurück zum Zitat Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39: 165-167. 10.1038/ng1959.CrossRef Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39: 165-167. 10.1038/ng1959.CrossRef
42.
Zurück zum Zitat Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM: BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001, 105: 149-160. 10.1016/S0092-8674(01)00304-X.CrossRef Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM: BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001, 105: 149-160. 10.1016/S0092-8674(01)00304-X.CrossRef
43.
Zurück zum Zitat Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D: Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007, 44: 726-731. 10.1136/jmg.2007.051268.CrossRef Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, Oliveira C, Collins L, Schnitt S, Garber JE, Huntsman D: Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet. 2007, 44: 726-731. 10.1136/jmg.2007.051268.CrossRef
Metadaten
Titel
Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals
verfasst von
Kirsi M Kuusisto
Aleksandra Bebel
Mauno Vihinen
Johanna Schleutker
Satu-Leena Sallinen
Publikationsdatum
01.02.2011
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2011
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2832

Weitere Artikel der Ausgabe 1/2011

Breast Cancer Research 1/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.